Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity (2010 - 2026)

Neurocrine Biosciences' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $4.9 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 33.04% year-over-year to $4.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 billion (up 24.19% YoY) and the FY2025 annual result came in at $4.6 billion, up 24.55% from the prior year.
• Liabilities and Shareholders Equity was $4.9 billion for Q1 2026 at Neurocrine Biosciences, up from $4.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $4.9 billion in Q1 2026 and bottomed at $2.0 billion in Q2 2022.
• A 5-year average of $3.2 billion and a median of $3.3 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity rose 2.52% — and 2024, when it soared 47.15%.
• Neurocrine Biosciences' Liabilities and Shareholders Equity stood at $2.4 billion in 2022, then surged by 37.27% to $3.3 billion in 2023, then climbed by 14.37% to $3.7 billion in 2024, then gained by 24.55% to $4.6 billion in 2025, then rose by 5.93% to $4.9 billion in 2026.
• Business Quant data shows NBIX's Liabilities and Shareholders Equity at $4.9 billion in Q1 2026, $4.6 billion in Q4 2025, and $4.3 billion in Q3 2025.